We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+15.5%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.17B
AUM Growth
+$187M
Cap. Flow
-$13.4M
Cap. Flow %
-0.62%
Top 10 Hldgs %
27.68%
Holding
163
New
13
Increased
39
Reduced
20
Closed
16

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$28M
2
IRTC icon
iRhythm Holdings
IRTC
+$17.5M
3
PBYI icon
Puma Biotechnology
PBYI
+$13.4M
4
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$10.8M
5
MOH icon
Molina Healthcare
MOH
+$10.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$37.9M
2
HUM icon
Humana
HUM
+$31.9M
3
HOLX
Hologic
HOLX
+$19.1M
4
MDT icon
Medtronic
MDT
+$12.7M
5
WBA
Walgreens Boots Alliance
WBA
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 80.49%
2 Financials 3.75%
3 Consumer Discretionary 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SAGE
126
DELISTED
Sage Therapeutics
SAGE
$2.02M 0.09%
+32,500
New +$2.55M
SCYX icon
127
SCYNEXIS
SCYX
$52M
$1.83M 0.08%
9,500
– –
ALPN
128
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.74M 0.08%
150,000
– –
MYOK
129
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.71M 0.08%
+40,000
New +$1.28M
DMTX
130
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.35M 0.06%
225,000
-46,370
-17% -$120K
CHMA
131
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.26M 0.06%
492,500
– –
KA
132
DELISTED
Kineta, Inc. Common Stock
KA
$945K 0.04%
3,214
– –
NVAX icon
133
Novavax
NVAX
$1.31B
$935K 0.04%
41,000
– –
LUMO
134
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$738K 0.03%
8,056
– –
KALA icon
135
KALA BIO
KALA
$14.5M
$571K 0.03%
+10
New +$549K
TNDM icon
136
Tandem Diabetes Care
TNDM
$1.56B
$411K 0.02%
56,250
– –
EGLT
137
DELISTED
Egalet Corporation
EGLT
$384K 0.02%
300,000
– –
INFI
138
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$359K 0.02%
270,000
– –
OREX
139
DELISTED
Orexigen Therapeutics, Inc.
OREX
$350K 0.02%
165,300
– –
DARE icon
140
Dare Bioscience
DARE
$21M
$195K 0.01%
5,208
– –
ANTH
141
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$155K 0.01%
107,630
-58,075
-35% -$82.5K
ALKS icon
142
Alkermes
ALKS
$8.25B
– –
-52,000
Closed -$3.01M
GKOS icon
143
Glaukos
GKOS
$10.6B
– –
-62,500
Closed -$2.59M
CBIO
144
Crescent Biopharma
CBIO
$626M
– –
-2,250
Closed -$2.51M
HOLX
145
DELISTED
Hologic
HOLX
– –
-420,000
Closed -$19.1M
HUM icon
146
Humana
HUM
$46.2B
– –
-132,500
Closed -$31.9M
INVA icon
147
Innoviva
INVA
$1.48B
– –
-200,000
Closed -$2.56M
LXRX icon
148
CALL
Lexicon Pharmaceuticals
LXRX
$1.1B
– –
-393,500
Closed -$6.47M
PRGO icon
149
Perrigo
PRGO
$1.78B
– –
-9,800
Closed -$740K
WBA
150
DELISTED
Walgreens Boots Alliance
WBA
– –
-86,000
Closed -$6.74M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Rock Springs Capital Management held 163 positions worth $2.17B, up 9.5% from $1.98B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management's Q3 2017 filing shows 13 new, 39 increased, 20 reduced and 16 closed positions. Its largest new stake was iRhythm Holdings: 386,000 shares worth $20M. The largest sale was Allergan plc, an estimated $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q3 2017 buy was iRhythm Holdings: 386,000 shares worth $20M.
  • Rock Springs Capital Management added most to UnitedHealth in Q3 2017, an estimated $28M increase.
  • Rock Springs Capital Management's biggest Q3 2017 reduction was Medtronic, cutting an estimated $12.7M.
  • Rock Springs Capital Management fully exited Allergan plc in Q3 2017, selling an estimated $37.9M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $2.17B portfolio in Q3 2017.
  • Rock Springs Capital Management opened 13 new positions and closed 16 in Q3 2017.
  • Rock Springs Capital Management's portfolio value rose 9.5% quarter-over-quarter to $2.17B.

Based on Rock Springs Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.